MINNEAPOLIS, Nov. 30, 2016 -- GWG Holdings, Inc. (Nasdaq:GWGH), a specialty finance company and a leading purchaser in the life insurance secondary market, is pleased to announce its participation in the three-day LD Micro Main Event December 6-8, 2016 at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.
Jon Sabes, Chief Executive Officer, and Bill Acheson, Chief Financial Officer, will be presenting at the conference on Wednesday, December 7th at 7:30AM Pacific Time. In addition to presenting, GWG will be attending one-on-one meetings with investors throughout that day.
GWG recently announced that it has acquired the rights for the exclusive license of “DNA Methylation Based Predictor of Mortality” technology from the University of California, Los Angeles (UCLA). The technology was discovered by Dr. Steve Horvath and is featured in the September 2016 edition of “Aging”.
“We believe Dr. Horvath’s technology will revolutionize the prediction of human longevity,” commented Jon Sabes, Chief Executive Officer. “We expect to immediately implement this technology into our current business to enhance our actuarial underwriting precision. In addition, we intend to explore a more comprehensive application of this technology to the life insurance business. While we have some work to complete, we believe we may hold some of the most innovative financial technology the life insurance industry has seen in over a century.”
More information regarding the DNA Methylation Based Predictor of Mortality technology and a discussion on the implications for GWG’s current business, as well as its potential application to the wider insurance industry, can be found on our website at www.gwgh.com.
To receive additional information or to schedule a one-on-one meeting, please contact Larry Clark at (310) 622-8223.
About GWG Holdings, Inc.
GWG Holdings, Inc. (Nasdaq:GWGH) is a specialty finance company and a leader in the life insurance secondary market. GWG is dedicated to creating a vibrant life insurance secondary market for the economic benefit of seniors with life insurance who are seeking post-retirement financial solutions, investors seeking yield derived from non-correlated assets, financial advisors seeking value-added products and services for their clients, and shareholders seeking to gain from the realization of this marketplace. As of September 30, 2016, GWG’s growing portfolio consisted of over $1.27 billion in face value of policy benefits. Since 2006, GWG has purchased over $2.2 billion in life insurance policy benefits and paid seniors more than $379 million for their life insurance.
For more information about GWG Holdings, email [email protected] or visit www.gwgh.com.
Investor Contacts: Larry Clark (310) 622-8223 Financial Profiles, Inc. [email protected] Media Contacts: Dan Callahan Director of Communication GWG Holdings, Inc. (612) 746-1935 [email protected]


John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 



